Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-HT)(1A) agonists acutely reduce these complications, their prophylactic and long-term effects are not well-delineated. To test this, male Sprague-Dawley rats received unilateral 6-hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). Rats were tested for LID using the abnormal involuntary movements (AIMs) scale and motor performance using the forepaw adjusting steps test (FAS). In experiment 2, l-DOPA-naïve rats received co-administration of l-DOPA+buspirone (1.0 or 2.5 mg/kg, ip) for 2 weeks. AIMs and FAS were measured throughout. In l-DOPA-primed rats, buspirone dose-dependently reduced LID and improved l-DOPA-related motor performance due to action at the 5-HT(1A) receptor. In l-DOPA-naïve rats, buspirone delayed LID development while improving l-DOPA's anti-parkinsonian efficacy indicating the potential long-term benefits of 5-HT(1A) agonists for reduction of l-DOPA-related side effects.
Dopamine ( DA ) replacement therapy with l - DOPA remains the standard pharmacotherapy for Parkinson 's disease ( PD ) . Unfortunately , chronic l - DOPA treatment is accompanied by development of motor fluctuations and l - DOPA - induced dyskinesia ( LID ) . While serotonin ( 5-HT)(1A ) agonists acutely reduce these complications , their prophylactic and long - term effects are not well - delineated . To test this , male Sprague - Dawley rats received unilateral 6-hydroxydopamine ( 6-OHDA ) lesions . In experiment 1 , l - DOPA - primed rats were pre - treated with Vehicle ( 0.9 % NaCl ) , various doses of the partial 5-HT(1A ) agonist , buspirone ( 0.25 , 1.0 or 2.5 mg / kg , ip ) or buspirone ( 2.5 mg / kg , ip)+the 5-HT(1A ) antagonist , WAY100635 ( 0.5 mg / kg , ip ) 5 min prior to l - DOPA ( 12 mg / kg+15 mg / kg benserazide , ip ) . Rats were tested for LID using the abnormal involuntary movements ( AIMs ) scale and motor performance using the forepaw adjusting steps test ( FAS ) . In experiment 2 , l - DOPA - naïve rats received co - administration of l - DOPA+buspirone ( 1.0 or 2.5 mg / kg , ip ) for 2 weeks . AIMs and FAS were measured throughout . In l - DOPA - primed rats , buspirone dose - dependently reduced LID and improved l - DOPA - related motor performance due to action at the 5-HT(1A ) receptor . In l - DOPA - naïve rats , buspirone delayed LID development while improving l - DOPA 's anti - parkinsonian efficacy indicating the potential long - term benefits of 5-HT(1A ) agonists for reduction of l - DOPA - related side effects .
Which drug is benserazide usually co-administered with?
Which drug is benserazide usually co - administered with ?
L-Dopa
L-Dopa